Abstract
To evaluate the risk of epilepsy in children who received neonatal phototherapy. A cohort of live singletons born at a Danish hospital (2002–2016) with a gestational age ≥ 35 weeks. We used Cox regression to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) of epilepsy in children treated with neonatal phototherapy compared to children not treated with neonatal phototherapy in the general population, and in a subpopulation of children who had serum bilirubin measurement. Adjusted HRs (aHR) were computed using multivariable and propensity score matching models to take maternal and neonatal factors into consideration. Children were followed from day 29 after birth to diagnosis of epilepsy, death, emigration, or December 31, 2016. Among 65,365 children, 958 (1.5%) received neonatal phototherapy. Seven children (incidence rates (IRs): 10.8 /10,000 person-years) who received neonatal phototherapy and 354 children (IR: 7.7) who did not receive neonatal phototherapy were diagnosed with epilepsy. Neonatal phototherapy was not associated with an increased risk of epilepsy using the multivariable (aHR 0.95, 95% CI: 0.43–2.09) and propensity score matched (aHR 0.94, 95% CI: 0.39–2.28) models. In the subpopulation of 9,378 children with bilirubin measurement, 928 (9.9%) received neonatal phototherapy. In the analysis of the subpopulation in which bilirubin level and age at the time of bilirubin measurement were further taking into consideration, neonatal phototherapy was not associated with an increased risk of epilepsy using the multivariable (aHR 1.26, 95% CI: 0.54–2.97) and propensity score matched (aHR 1.24, 95% CI: 0.47–3.25) models,
Conclusions: Neonatal phototherapy was not associated with an increased risk of epilepsy after taking maternal and neonatal factors into consideration.
What is known: • A few studies have suggested that neonatal phototherapy for hyperbilirubinemia may increase the risk of childhood epilepsy. • Whether the observed associations contribute to hyperbilirubinemia, phototherapy, or underlying factors requires further investigation. |
What is new: • This study revealed no increased risk of epilepsy in children treated with neonatal phototherapy compared to children not treated with phototherapy after taking maternal and neonatal factors into consideration. • After further taking bilirubin level and age at the time of bilirubin measurement into consideration, neonatal phototherapy was not associated with an increased risk of epilepsy. |
Similar content being viewed by others
Explore related subjects
Discover the latest articles, news and stories from top researchers in related subjects.Avoid common mistakes on your manuscript.
Introduction
Kernicterus, once prevalent due to neonatal hyperbilirubinemia, is now rare owing to improved care and treatment methods [1,2,3,4,5]. However, bilirubin neurotoxicity, encompassing a spectrum known as kernicterus spectrum disorder (KSD), remains a concern [1, 5, 6]. Phototherapy, alongside exchange transfusion in severe cases, is the standard treatment for hyperbilirubinemia in newborns [7, 8]. Despite its efficacy, concerns persist regarding potential adverse effects such as allergy, neurological disorders, and cancer [9,10,11,12]. Previous studies have suggested an increased risk of seizures or epilepsy in children undergoing neonatal phototherapy, yet determining causality between hyperbilirubinemia, neonatal phototherapy, and epilepsy remains challenging [10, 13]. In this study, we sought to contribute further evidence to this topic using Danish registry data from a university hospital.
Methods
Study design and study population
We conducted a cohort study utilizing data from the Danish Medical Birth Registry [14] to identify all live singleton births with a gestational age of ≥ 35 weeks at Aarhus University Hospital between January 1, 2002, and November 30, 2016. The study population comprised infants with available data on birth weight, who survived the neonatal period, and remained resident in Denmark on day 29 post-birth (N = 65,365; see Supplementary Fig. 1). In Denmark, each resident is assigned a unique identification number in the Danish Civil Registration System, facilitating accurate data linkage across national registers [15, 16]. Only children born at Aarhus University Hospital were included in this study due to incomplete information on neonatal phototherapy in other regions of Denmark [17]. We used data from the Danish registries and no consent forms are needed according to Danish data protection regulation. Our research adhered to the ethical principles outlined in the Declaration of Helsinki and the study was approved by the Danish Data Protection Agency (reference number: 2016–051-000001, serial number 1515, approval date: 11. June 2019). We utilized ChatGPT to assist in revising the language of our manuscript, but we carefully reviewed and incorporated the revisions.
Information on measurements of bilirubin
Data on bilirubin measurements, including total serum bilirubin and unconjugated bilirubin, were extracted from the clinical laboratory information system (LABKA). Implemented in 2000 within the Central Denmark Region, LABKA offers comprehensive coverage within this region, encompassing Aarhus University Hospital [18]. The system aggregates test results from samples collected in both public and private hospitals, as well as those collected by general practitioners and submitted to clinical biochemistry departments.
Key test items during the neonatal period included total serum bilirubin (TsB) of neonates (NPU04145), total serum bilirubin (NPU01370), unconjugated bilirubin (NPU01366), and conjugated bilirubin (NPU17194), with the NPU terminology employed for result identification and communication across clinical laboratories [18].
The dataset contains details such as sampling date and time, results, and units of tests conducted. For this study, bilirubin measurement primarily pertains to total serum bilirubin and/or unconjugated bilirubin, given the negligible presence of conjugated bilirubin during the neonatal period. Multiple bilirubin measurements could be recorded for a child during this period, with the highest value selected for analysis.
Information on neonatal phototherapy
Data on neonatal phototherapy treatment were extracted from the Danish National Patient Register (DNPR) [19]. Children receiving neonatal phototherapy were identified if they were coded with procedure codes BNGC (Phototherapy) or BNGC0 (Phototherapy to neonates) in the DNPR, with treatment dates falling within the neonatal period (up to 28 days of age). Clinical practices adhere to phototherapy guidelines for neonatal hyperbilirubinemia adapted by the Danish Pediatric Society in 1992 and 2012 from guidelines established by the American Academy of Pediatrics (see Supplementary Table 1a) [2, 20]. The information about the devices, light spectrum, intensity used for neonatal phototherapy at Aarhus University Hospital could be found in the Supplementary Table 1b. Since 2011, the Danish recommendation of intensity for neonatal phototherapy is a minimum 30 microwatts/cm2/nm, measured at initiation. Phototherapy usually last for 24 h before taking a bilirubin measurement to judge if the treatment should continue or not (personal communication with coauthor JPP).
Information on diagnosis of epilepsy
Diagnoses of epilepsy were retrieved from the DNPR [21]. Children were classified as having epilepsy if they were registered with ICD-10 codes G40-G41 as either a primary or secondary diagnosis after the neonatal period. The date of epilepsy onset was defined as the date of hospital contact that led to the diagnosis.
Information on covariates
Data on date and time of birth, sex of the child, gestational age at birth, birth weight, Apgar score at five minutes, maternal age at the time of birth, and parity were obtained from the Danish Medical Birth Registry. The age of the child in hours at the time of blood sample collection for bilirubin tests was determined by utilizing both the date and time of birth and blood sample collection.
Children were classified based on gestational age and birth weight percentile: those with a birth weight below the 10th percentile for their gestational age were categorized as small for gestational age (SGA), those with a birth weight above the 10th percentile were classified as large for gestational age (LGA), and those with a birth weight between the 10th and 90th percentile were deemed appropriate for gestational age (AGA). Information on family disposable income was obtained from Statistics Denmark [22].
Diagnoses of major congenital malformations in the neonatal period (within 28 days after birth) were extracted from the DNPR. Information on major congenital malformations (see Supplementary Table 2), other neonatal factors (see Supplementary Table 3) during the neonatal period, as well as maternal factors during pregnancy (see Supplementary Table 4), were also obtained from the DNPR.
Statistics
Characteristics of children were summarized for children with neonatal phototherapy and children without neonatal phototherapy among the total population and among children with available measurement of bilirubin. For children with measurement of bilirubin, we estimated mean and standard deviation of the maximum of bilirubin measured in the neonatal period and the age of neonates at time of bilirubin measurement.
Crude and adjusted hazard ratios (HRs) of epilepsy for children with neonatal phototherapy compared to those without neonatal phototherapy were estimated using Cox proportional regression models. Children were followed from day 29 after birth until the onset of epilepsy, death, emigration, or the end of follow-up on December 31, 2016. Age served as the time scale in the Cox proportional regression models.
Adjusted HRs of epilepsy were calculated in two ways, the traditional multivariable model and propensity score matching model, since the propensity score matching model enable us to take more covariates into account than the traditional one. In the analyses using the multivariable model [23], each factor (including sex, gestational age, intrauterine growth [SGA, AGA, LGA], congenital malformation, Apgar score, neonatal and maternal risk factors, birth year, family income, maternal age, and parity) was included as an independent variable. In the analyses using propensity score matching, propensity scores of neonatal phototherapy were computed based on child and maternal risk factors (27 in total, see Table 1). We employed a 1:3 ratio using nearest neighbor matching with a caliper of 0.1 of the standard deviation of the logit of the propensity score and ensured common support of propensity score (overlap in the propensity score distribution between the treatment and control groups) [24]. We did balancing test of neonatal and maternal factors between children with neonatal phototherapy and children without neonatal phototherapy before and after propensity score matching.
We conducted similar analyses in the subgroup of children who had at least one bilirubin measurement in the neonatal period enabling us to further adjust for bilirubin related factors and estimate the influence of phototherapy itself on epilepsy risk. In the multivariable model, we further adjusted for gestational age- and age-specific quartiles of bilirubin level (1st, 2nd, 3rd, 4th quartile) and age at the time of bilirubin measurement (1st, 2nd,3rd, 4th, 5–7, 8–14, 15–21, and 22–28 days after birth). For propensity score matching, we included gestational age- and age-specific quartiles of bilirubin level and age at the time of bilirubin measurement in the calculation of the propensity score of neonatal phototherapy (see Table 1). To obtain gestational age- and age-specific quartiles of bilirubin, children were categorized into quartiles within each stratum based on gestational age (35, 36, 37, 38, or ≥ 39 gestational weeks) and age at the time of bilirubin measurement (< 48 h, 48–71 h, 72–95 h, 4–14 days, and 15–28 days).
All analyses were performed with STATA, version 16 (StataCorp LLC, College Station, TX, USA).
Results
In the total study population (n = 65,365), 958 (1.5%) children received neonatal phototherapy treatment in the neonatal period. Children undergoing neonatal phototherapy exhibited a higher prevalence of adverse conditions compared to those without neonatal phototherapy (Table 1). Over a mean follow-up period of 7.2 years (up to 15 years), seven children (incidence rate [IR] 10.8/10,000 person-years) were diagnosed with epilepsy among those receiving neonatal phototherapy, while 354 children (IR 7.7/10,000 person-years) were diagnosed with epilepsy among those without neonatal phototherapy. The adjusted hazard ratio (HR) for epilepsy in children with neonatal phototherapy compared to those without was 0.95 (95% CI: 0.43–2.09) in the multivariable model and 0.94 (95% CI: 0.39–2.28) in the propensity matching model (Table 2). In the analyses using the propensity score matching model, child and maternal factors were balanced between children with and without neonatal phototherapy (Fig. 1A, Supplementary Table 5).
In the subpopulation (n = 9,378) with bilirubin measurement in the neonatal period, 928 (9.9%) children received neonatal phototherapy. Similarly, children with neonatal phototherapy exhibited a higher prevalence of adverse conditions compared to those without neonatal phototherapy, except for birth asphyxia, acidosis, and neonatal convulsion/intracranial hemorrhage, where children with neonatal phototherapy showed lower prevalence rates of these factors (Table 1). Children who underwent neonatal phototherapy had higher bilirubin levels compared to children without neonatal phototherapy (Table 3). Bilirubin measurements for children with neonatal phototherapy were more likely to occur around 4–7 days after birth, while children without neonatal phototherapy had a more varied distribution of bilirubin measurements (Table 1, Table 3). During follow-up, seven children (IR 11.2/10,000 person-years) were diagnosed with epilepsy among those receiving neonatal phototherapy, compared to 86 children (IR 15.9/10,000 person-years) among those without neonatal phototherapy. The adjusted HR for epilepsy in children with neonatal phototherapy compared to children without neonatal phototherapy was 1.26 (95% CI: 0.54–2.97) in the multivariable model and 1.24 (95% CI: 0.47–3.25) in the propensity matching model (Table 4). In the analyses using the propensity score matching model, child and maternal factors were balanced between children with and without neonatal phototherapy (Fig. 1B, Supplementary Table 5).
Discussion
This study showed that children who underwent neonatal phototherapy did not have an increased risk of epilepsy compared to children without neonatal phototherapy in the general population. We also found no increased risk of epilepsy associated with neonatal phototherapy in children who had bilirubin measurements, in which bilirubin level and age at the time of bilirubin measurement were further taken into consideration besides many other maternal and neonate’s factors. The finding was robust when accounting for potential confounders using different statistical models.
Our study findings diverged from those of previous studies conducted in Denmark [13] and the US [10]. Maimburg et al. (2016) reported a 1.6-fold (95%CI: 1.23–2.24) increased risk of epilepsy among children who underwent neonatal phototherapy, particularly in boys [13], whereas Newman et al. (2018) found a 1.3-fold (95%CI: 1.10–1.61) increased risk of seizures in boys who received neonatal phototherapy compared to those who had bilirubin measurements but did not receive neonatal phototherapy [10]. Methodological differences and variations in healthcare systems may contribute to these discrepancies. The study by Maimburg et al. (2016) collected information on neonatal phototherapy reported by mothers and included children born both ≥ 35 gestational weeks and below 35 gestational weeks [13]. The primary outcome in the US study by Newman et al. (2018) was defined as those with at least one seizure diagnosis and at least one antiseizure medication prescription, providing a slightly different perspective [10]. Notably, the proportion of children receiving neonatal phototherapy in the US study (7.6%) was higher than in ours (1.5% in the study population in which neonatal death were not included and 1.6% in the general population [17]), despite both focusing on children born ≥ 35 gestational weeks. Furthermore, the proportion of children receiving neonatal phototherapy in the US study increased significantly from 2.4% to 15.9% during the study period (1995–2011), [25] whereas the proportion in our study remained stable during the study period (2002–2016) [17]. Fortunately, we could conduct similar analyses by restricting to children with bilirubin measurement, akin to the US study.
The lower epilepsy incidence rate (unadjusted) and a non-significant increased risk after adjusting for potential confounders among children with bilirubin measurements undergoing neonatal phototherapy compared to children with bilirubin measurements without neonatal phototherapy, present an intriguing observation. It emphasizes the importance of adjusting for confounders and considering the complex interplay between phototherapy, bilirubin levels, and other potential risk factors for neurological outcomes. While phototherapy effectively reduces bilirubin levels, thereby mitigating the risk of bilirubin-induced neurotoxicity, it's possible that other mechanisms or confounding variables influence the risk of epilepsy independently [26].
Our study possessed both strengths and limitations. It was a population-based study with nearly complete follow up. Both information on neonatal phototherapy and serum bilirubin levels were derived from registers and recall bias was unlikely. The register provided detailed information on bilirubin measurements, enabling adjustment for bilirubin levels and measurement timing. However, information on the timing, duration, intensity, and frequency of neonatal phototherapy in our study was lacking, which may have impacted our ability to assess its effects comprehensively, for example dose–response relationship between neonatal phototherapy and risk of epilepsy. A Japanese observational cohort study demonstrated that a long duration of neonatal phototherapy was positively associated with the risk of allergic disorders in childhood [27]. Our study benefited from rich data on pregnancy, birth, and the post-natal period for both mothers and children. We employed two methods to adjust for potential confounders, including multivariable regression modeling and propensity score matching, with consistent findings. Our study's small sample size resulted in limited statistical power and our ability to conduct additional analyses, like stratification analyses for boys and girls. Perhaps therefore, this study was not able to assess previous findings of an increased risk of epilepsy among boys treated with neonatal phototherapy. [10, 13] While previous research has shown inconclusive results regarding a link between neonatal phototherapy and childhood neurological development, including epilepsy, our study adds to the growing body of evidence suggesting minimal to no risk of adverse neurocognitive effects. [28] However, larger and more comprehensive data sets, including timing and dose in terms of duration, intensity, and frequency of neonatal phototherapy are needed to elucidate relationship between neonatal phototherapy and children neurological development. Additionally, applying methodologies such as regression discontinuity design [29, 30] could provide rigorous causal inference regarding the safety of neonatal phototherapy on child neurological development [31,32,33,34]. Notably, our study took place in a setting where neonatal phototherapy was maintained at a reasonable low level (1.6% children born at 35 gestational weeks and later were registered with neonatal phototherapy). [17] Avoiding overtreatment of neonatal phototherapy may be recommended both to reduce health care costs and potential adverse effects, without increasing the rates of kernicterus. [28, 35]
Conclusions
Our study, based on a population-based cohort in Denmark, neonatal phototherapy for neonatal hyperbilirubinemia was not associated with an increased risk of epilepsy. The study had limited power, and further research is warranted to clarify the relationship between neonatal phototherapy and epilepsy risk.
Data Availability
The original data cannot be shared for data protection reasons. For questions on the original data, please contact Yuelian Sun, email: ys@clin.au.dk.
Abbreviations
- AGA:
-
Appropriate for gestational age
- CI:
-
Confidence interval
- DNPR:
-
Danish National Patient Register
- HR:
-
Hazard ratio
- ICD:
-
International Classification of Diseases
- LABKA:
-
Clinical laboratory information system
- LGA:
-
Large for gestational age
- SGA:
-
Small for gestational age
- TsB:
-
Total serum bilirubin
References
Riordan SM, Shapiro SM (2020) Review of bilirubin neurotoxicity I: molecular biology and neuropathology of disease. Pediatr Res 87(2):327–331. https://doi.org/10.1038/s41390-019-0608-0
Ebbesen F, Andersson C, Verder H et al (2005) Extreme hyperbilirubinaemia in term and near-term infants in Denmark. Acta Paediatr 94(1):59–64
Koziol LF, Budding DE, Chidekel D (2013) Hyperbilirubinemia: subcortical mechanisms of cognitive and behavioral dysfunction. Pediatr Neurol 48(1):3–13. https://doi.org/10.1016/j.pediatrneurol.2012.06.019
Lunsing RJ (2014) Subtle bilirubin-induced neurodevelopmental dysfunction (BIND) in the term and late preterm infant: does it exist? Semin Perinatol 38(7):465–471. https://doi.org/10.1053/j.semperi.2014.08.009
Wusthoff CJ, Loe IM (2015) Impact of bilirubin-induced neurologic dysfunction on neurodevelopmental outcomes. Semin Fetal Neonatal Med 20(1):52–57. https://doi.org/10.1016/j.siny.2014.12.003
Amin SB, Wang H (2015) Unbound unconjugated hyperbilirubinemia is associated with central apnea in premature infants. J Pediatr 166(3):571–575. https://doi.org/10.1016/j.jpeds.2014.12.003
Shapiro SM, Riordan SM (2020) Review of bilirubin neurotoxicity II: preventing and treating acute bilirubin encephalopathy and kernicterus spectrum disorders. Pediatr Res 87(2):332–337. https://doi.org/10.1038/s41390-019-0603-5
Bhutani VK, Stark AR, Lazzeroni LC et al (2013) Predischarge screening for severe neonatal hyperbilirubinemia identifies infants who need phototherapy. J Pediatr 162(3):477–82.e1. https://doi.org/10.1016/j.jpeds.2012.08.022
Hotta M, Ueda K, Ikehara S et al (2023) The Duration of Neonatal Phototherapy and Allergic Disorders: The Japan Environment and Children’s Study. Int Arch Allergy Immunol 184(3):211–219. https://doi.org/10.1159/000527381
Newman TB, Wu YW, Kuzniewicz MW, Grimes BA, McCulloch CE (2018) Childhood Seizures After Phototherapy. Pediatrics 142(4):e20180648. https://doi.org/10.1542/peds.2018-0648
Wickremasinghe AC, Kuzniewicz MW, Grimes BA, McCulloch CE, Newman TB (2016) Neonatal Phototherapy and Infantile Cancer. Pediatrics 137(6). https://doi.org/10.1542/peds.2015-1353
Wang J, Guo G, Li A, Cai WQ, Wang X (2021) Challenges of phototherapy for neonatal hyperbilirubinemia (Review). Exp Ther Med 21(3):231. https://doi.org/10.3892/etm.2021.9662
Maimburg RD, Olsen J, Sun Y (2016) Neonatal hyperbilirubinemia and the risk of febrile seizures and childhood epilepsy. Epilepsy Res 124:67–72. https://doi.org/10.1016/j.eplepsyres.2016.05.004
Bliddal M, Broe A, Pottegard A, Olsen J, Langhoff-Roos J (2018) The Danish Medical Birth Register. Eur J Epidemiol 33(1):27–36. https://doi.org/10.1007/s10654-018-0356-1
Schmidt M, Pedersen L, Sorensen HT (2014) The Danish Civil Registration System as a tool in epidemiology. Eur J Epidemiol 29(8):541–549. https://doi.org/10.1007/s10654-014-9930-3
Pedersen CB, Gøtzsche H, Møller JO, Mortensen PB (2006) The Danish Civil Registration System. A cohort of eight million persons. Dan Med Bull 53(4):441–9
Sun Y, Petersen JP, Wu C et al (2023) Neonatal Phototherapy and Clinical Characteristics: The Danish National Patient Registry 2000–2016. Clin Epidemiol 15:123–136. https://doi.org/10.2147/clep.S373289
Grann AF, Erichsen R, Nielsen AG, Froslev T, Thomsen RW (2011) Existing data sources for clinical epidemiology: The clinical laboratory information system (LABKA) research database at Aarhus University, Denmark. Clin Epidemiol 3:133–138. https://doi.org/10.2147/clep.s17901
Andersen TF, Madsen M, Jorgensen J, Mellemkjoer L, Olsen JH (1999) The Danish National Hospital Register. A valuable source of data for modern health sciences. Dan Med Bull 46(3):263–8
Padkær J, Møller M, Stanchev H et al (2012) Behandlingsstandard for neonatal hyperbilirubinæmi (Danish Paediatric Society). https://paediatri.dk/images/pdf_filer/dps_vejl/neo/008neo.pdf. Accessed 17 Nov 2023
Schmidt M, Schmidt SA, Sandegaard JL, Ehrenstein V, Pedersen L, Sorensen HT (2015) The Danish National Patient Registry: a review of content, data quality, and research potential. Clin Epidemiol 7:449–490. https://doi.org/10.2147/clep.s91125
Baadsgaard M, Quitzau J (2011) Danish registers on personal income and transfer payments. Scand J Public Health 39(7_suppl):103–5. https://doi.org/10.1177/1403494811405098
Bradburn MJ, Clark TG, Love SB, Altman DG (2003) Survival analysis part II: multivariate data analysis–an introduction to concepts and methods. Br J Cancer 89(3):431–436. https://doi.org/10.1038/sj.bjc.6601119
Austin PC (2014) The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments. Stat Med 33(7):1242–1258. https://doi.org/10.1002/sim.5984
Newman TB, Wickremasinghe AC, Walsh EM, Grimes BA, McCulloch CE, Kuzniewicz MW (2016) Retrospective Cohort Study of Phototherapy and Childhood Cancer in Northern California. Pediatrics 137(6). https://doi.org/10.1542/peds.2015-1354
Kujabi ML, Petersen JP, Pedersen MV, Parner ET, Henriksen TB (2021) Neonatal jaundice and autism spectrum disorder: a systematic review and meta-analysis. Pediatr Res 90(5):934–949. https://doi.org/10.1038/s41390-020-01272-x
Hotta M, Ueda K, Ikehara S et al (2023) Phototherapy and risk of developmental delay: the Japan Environment and Children’s Study. Eur J Pediatr 182(5):2139–2149. https://doi.org/10.1007/s00431-022-04785-1
Taylor JA (2018) Phototherapy and Seizures: Should We Change Practice? Pediatrics 142(4):e20182241
Bor J, Moscoe E, Mutevedzi P, Newell ML, Barnighausen T (2014) Regression discontinuity designs in epidemiology: causal inference without randomized trials. Epidemiology (Cambridge, Mass.) 25(5):729–37. https://doi.org/10.1097/ede.0000000000000138
Moscoe E, Bor J, Barnighausen T (2015) Regression discontinuity designs are underutilized in medicine, epidemiology, and public health: a review of current and best practice. J Clin Epidemiol 68(2):122–133. https://doi.org/10.1016/j.jclinepi.2014.06.021
(2018) Phototherapy and risk of epilepsy . . . and other stories. BMJ (Clinical research ed.) 363:k4265. https://doi.org/10.1136/bmj.k4265
Shoris I, Gover A, Toropine A et al (2023) "Light" on Phototherapy-Complications and Strategies for Shortening Its Duration, A Review of the Literature. Children (Basel) 10(10). https://doi.org/10.3390/children10101699
Ebbesen F, Vreman HJ, Hansen TWR (2022) Blue-Green (~480 nm) versus Blue (~460 nm) Light for Newborn Phototherapy-Safety Considerations. Int J Mol Sci 24(1). https://doi.org/10.3390/ijms24010461
Grosse SD, Prosser LA, Botkin JR (2019) Screening for Neonatal Hyperbilirubinemia-First Do No Harm? JAMA Pediatr 173(7):617–618. https://doi.org/10.1001/jamapediatrics.2019.1194
Kemper AR, Newman TB, Slaughter JL et al (2022) Clinical Practice Guideline Revision: Management of Hyperbilirubinemia in the Newborn Infant 35 or More Weeks of Gestation. Pediatrics 150(3):e2022058859. https://doi.org/10.1542/peds.2022-058859
Acknowledgements
This study was supported by the Independent Research Fund Denmark (IRFD) – project number 9039-00296B. There is no role of the funding in study design, analysis, manuscript writing, interpretation of findings, and in the decision to submit the paper for publication.
Funding
Open access funding provided by Aarhus University Hospital.
Author information
Authors and Affiliations
Contributions
Y.S. obtained funding, conceived, and designed the study, performed the statistical analyses, drafted the manuscript, and critically reviewed and revised the manuscript; J.W.D., C.W., J.C., and R.D.M. conceived and designed the study, and critically reviewed and revised the manuscript. J.P.P., and T.B.H. critically reviewed and revised the manuscript. All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.
Corresponding author
Ethics declarations
Ethics approval
The study was approved by the Danish Data Protection Agency.
Competing interests
The authors have no relevant financial or non-financial interests to disclose.
Additional information
Communicated by Gregorio Milani
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Jakob Christensen and Rikke Damkjær Maimburg are contributed equally as co-senior authors.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Sun, Y., Dreier, J.W., Wu, C. et al. Neonatal phototherapy and risk of epilepsy—A Danish population based study. Eur J Pediatr 183, 4111–4121 (2024). https://doi.org/10.1007/s00431-024-05681-6
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00431-024-05681-6